FDA Inspection 1007184 — GlaxoSmithKline Biologicals SA
The FDA completed an inspection of GlaxoSmithKline Biologicals SA on Jan 27, 2017 in Rixensart. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Biologics.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Jan 27, 2017
- Fiscal Year
- 2017
- Product Type
- Biologics
- Project Area
- Vaccines and Allergenic Products
- Location
- Rixensart (Belgium)